A biotech startup co-founded by Sachdev Sidhu, a professor in U of T’s Department of Molecular Genetics, has drawn in $62 million USD following a second round of funding, bringing its total investments to $72 million USD.

Pionyr Immunotherapeutics, which is now planning to take its anti-cancer therapy to clinical trials, initially began as a research collaboration between Sidhu and Max Krummel, a professor at the University of California, San Francisco School of Medicine. Founded in 2015, the California-based startup combined Sidhu’s expertise in antibody phage-display technology with Krummel’s immune system biology research.

This project is a collaborative effort with Toronto Recombinant Antibody Centre (TRAC), which was founded by Sidhu and Dr. Jason Moffat, who is also a Molecular Genetics professor at U of T. Housed in the Donnelly Centre for Cellular and Biomolecular Research, TRAC researchers are working to harness the therapeutic potential of synthetic antibodies.

Synthetic antibodies can be engineered to target a variety of molecules implicated in disease and they are key for drug development. Pionyr’s anti-cancer therapy, known as Myeloid Tuning, uses the high specificity afforded by synthetic antibodies to bolster the immune system’s defence against cancer by manipulating a tumour’s microenvironment.

The immune system uses T cells to detect foreign molecules to evoke a defensive response. Because tumours are created from existing cells in the body, they evade recognition by T cells, dampen the immune response, and proliferate uncontrollably. The key is to restore the body’s immune capacity to fight cancer — this is the premise of immunotherapy in oncology, better known as immuno-oncology.

“So the idea there is simple: you want to turn on a T cell, you simply find proteins that are inhibiting that T cell,” said Sidhu.

Myeloid Tuning achieves this by “alter the tumour microenvironment to favour immune-activating cells over immune-suppressing cells” and enhances anti-tumour defenses. “T cells are activated not by targeting them but by eliminating the inhibitory cell population,” said Sidhu.

Pionyr’s technology could also complement existing anti-tumour therapies like T cell checkpoint inhibitors. Checkpoints are regulators that mediate communication between T cells and the immune system. They are responsible for fine-tuning the body’s immunity and downregulating it when it detects native cells, which would otherwise lead to an autoimmune response. By incorporating checkpoint inhibitors, therapies can be developed to block a tumour’s ability to evade T cell detection.

Ipilimumab, commercially known as Yervoy, set the precedent by becoming the first United States Food and Drug Administration-approved therapeutic antibody against skin cancers and for ushering in a new wave of immuno-oncology. The drug, co-invented by Krummel, inhibits cytotoxic T-lymphocyte-associated protein-4, one of many checkpoints found on T cells. Similarly, pembrolizumab, or Keytruda, inhibits the checkpoint called programmed cell death protein 1 (PD-1).

“Anti-PD-1 binds the T cell and… activates it that way, and then we add another antibody that eliminates inhibitory myeloid cells, so you get double [the effect],” said Sidhu.

Sidhu says there is a critical question in field: does the rest of the tumour simply not have T cells that can attack them or are there additional yet unidentified breaks? These possibilities are not mutually exclusive and are already being investigated. According to Sidhu, the future of immuno-oncology is already here.

Myeloid Tuning is a very promising method, but it is not the only immuno-oncology treatment in the works. Currently, therapeutic agents being researched involve other immune cells like macrophages and natural killer cells that can be exploited for anti-tumour therapies.

“[There is] very little that is not being explored as far as immune cell activation,” said Sidhu. “It’s exciting in that, while only a subset of cancers responds to immunotherapy, the ones that do respond often respond tremendously.”

Quick and accurate diagnosis is vital to effective treatment, anything that can make pathology more efficient might be a literal life-saver.

Pathcore, a start-up based at the University of Toronto’s Impact Centre, aids this process by employing the power of computerized quantitative methods to transform the field of pathology. Using algorithm-based image analysis, the start-up helps pathologists make diagnoses more accurately and more efficiently.

“Pathology is a very analogue field that still relies on microscopes and human interpretation to diagnose complex diseases,” says Dan Hosseinzadeh, CEO and co-founder of the start-up. “We feel that computers can assist the pathologists in certain routine, time consuming, and tedious tasks, thereby allowing the human pathologists to focus on the complex decision-making by synthesizing information from various sources into a diagnosis.”

The Sedeen Viewer, is one of Pathcore’s products that allows pathologists to annotate and analyze whole slide scans of tissue samples. Pathologists can then apply tissue- and disease-specific algorithms to the images to make clinical diagnoses.

Sean Nichols, Pathcore’s Lead Web Developer explains that, “for prostate cancer, you might have an algorithm that calculates what’s called the Gleason score, which is a scoring method for grading the aggressiveness of prostate cancer. In that case you might look across the whole image or select a few areas that are representative, and then run the algorithm on it.”

Pathcore has also developed assisted algorithms that automate repetitive tasks such as cell counting. “So right now pathologists would look at an area and say there’s about 200 cells, whereas an algorithm could tell you exactly how many it detects,” says Nichols.

“The main challenge is coping with the vast amount of information available when specimens are imaged at high resolution… Also understanding the complex nature of the disease process is challenging and important for building good algorithms,” says Hosseinzadeh.

Pathcore’s technology is currently being used by over 100 organizations around the world. The $4 million (CAD) investment from the US’ National Cancer Institute will accelerate algorithm development for cancer detection. This investment will allow the company to expand its Software Development Kit to support its partner institutions as they build their own algorithms.

Additionally, the company is “hoping to improve on the usability of the [Sedeen Viewer] and potentially hire some more developers to improve the software,” says Deyu Wang, product designer at Pathcore.

The start-up is a spin-off from a research project originally supported by the Ontario Institute for Cancer Research and the Sunnybrook Research Institute.

The Impact Centre nurtures early stage start-ups by providing a range of services, including marketing, consulting, and legal support. It also provides a physical space for start-ups at little or no cost. Nichols explains that the Impact Centre “puts all these start-ups in an environment together to kind of interact with each other and give each other advice.”

U of T students interested in working at a start-up should enroll in IMC200 (Innovation and Entrepreneurship) and IMC390 (Internships in New Ventures). The latter allows students to complete a placement at an Impact Centre Company.

The three characteristics of a successful start-up, Hosseinzadeh argues are, “a dedicated and hardworking team, a niche product, [and] a strong network.”

In 1961, Toronto researchers verified the existence of stem cells. Now, in 2016, a Canadian ‘Dream Team’ of researchers assembles to tackle cancer stem cells.

Announced on World Cancer Day, Dr. Peter Dirks, a neurosurgeon at the Hospital for Sick Children and a professor in the departments of surgery and molecular genetics at the University of Toronto, will lead this $11.7 million initiative funded by Stand Up to Cancer (SU2C), among other organizations.

Co-led by Dr. Samuel Weiss, director of the Hotchkiss Brain Institute at the University of Calgary, the team brings together scientists across Canada in a collaborative approach to make a difference for children and adults with brain cancer.

“The [goal of this] project is to understand brain cancer from a cancer stem cell perspective,” says Dr. Gary Bader, a Dream Team principal investigator of the Donnelly Centre for Cellular and Biomolecular Research. “The best treatments [currently] are not very effective. They do extend your life by…a few months.”

The Dream Team is dedicated to translational research, which aims to move discoveries from the lab and implement them in medical practices by bringing new treatments for brain cancer into clinical trials.

The primary targets are cancers known as glioblastomas and ependymomas, both of which are types of brain tumours. Less than 10 per cent of adults with glioblastoma survive for five years after diagnosis, and brain tumours are now the leading cause of death in children with cancer.

When healthy, stem cells in the brain will develop into normal nerve cells. Certain stem cells with deleterious changes, on the other hand, can become cancerous. These cancerous stem cells can regenerate tumours even after surgery and therapy. Many cancerous stem cells will resist drug treatments as well.

The researchers intend to approach this challenge in three ways: first they will conduct a detailed analysis of brain tumour stem cells to better understand the biological profile of these cells. Then, they will explore new drug combinations through a careful screening of chemicals. Finally, the team will test five promising drugs in clinical trials that may potentially be the solution to glioblastomas and ependymomas.

Dr. Amy Caudy, a professor in the department of molecular genetics and Canada Research Chair in Metabolics for Functional Enzyme Discovery, is a Dream Team principal investigator. As part of the interdisciplinary approach against brain cancer, her team is investigating the links between cancer cells and metabolism, specifically a metabolite (a chemical produced in the body during digestion) called 2-hydroxyglutarate (2HG).

“[2-HG is] very central to the pathogenesis of at least some of these glioblastomas,” says Dr. Caudy, emphasizing the disease-triggering abilities of 2-HG.  “People are now using it as a biomarker for [the] progression and status of glioblastomas and also some other cancers.”

With project leaders Dr. Dirks, who first discovered brain cancer stem cells, and Dr. Weiss, who received the Canada Gairdner International Award for discovering adult neural stem cells, the team of fourteen researchers stand up to cancer. Together, the Dream Team continues Canada’s legacy in stem cell research.

Stephanie Rudnick is a former Varsity Blues basketball player who played for current U of T head coach Michele Belanger during the 1994-1999 seasons. In 1999, Rudnick was intent upon playing out her final year of eligibility wearing blue and white. She had goals to “win a National Championship, become an OUA All Star, an All Canadian, and then play pro in Israel.” Following these achievements, Rudnick planned to return to Canada and start her own basketball camp. 

Playing through several back injuries, Rudnick was named an OUA All Star in her fourth year. Before being able to check another goal off her list, Rudnick’s life took an unexpected turn. In May 1999, her father was diagnosed with stage four cancer, and passed away only two months after his diagnosis. Devastated and injured, Rudnick did not return to the Blues that fall and was forced to revise a plan that she had dedicated years of her life to fulfilling.

No pro contract, no business education, and in the midst of a devastating loss, Rudnick was left without direction. “Feeling self-defeated I cried to him about how my old plan was ruined,” Rudnick explained how she reacted when a friend asked about what she would do next.

It was only after this meeting and some serious thought that Rudnick conceptualized Elite Camps. Born out of pain, Elite Camps is one of the largest and longest running basketball organizations in Canada. Based in the GTA, Elite Camps sees more then 3,000 kids every year and is in its seventeenth year of operation.

To avoid competition with rival clubs, Rudnick explains that her first camp was launched over the holidays: “I found out that Passover was a time with no programming. I decided I would try to run my first camp at that time [to avoid competing with other camps in the GTA].”

Rudnick pursued mentorship from another camp director, joined the Ontario Camping Association, and reached out to her former Varsity Blues teammates to work at her camp. What started as one camp in Toronto soon grew into two, and now Elite Camps runs over 37 sessions in multiple cities.

Next came Swish for the Cure. “A few years after I started my business I really wanted to do something to honour [my father’s] memory,” Rudnick explained, which is how Swish for the Cure — celebrating its tenth anniversary on February 6, started. Swish for the Cure has raised over $135,000 to date for in the name of the Childhood Cancer Foundation. Rudnick explained that the event has evolved in the past ten years from a way to raise money for cancer research, to an opportunity to provide families of children with fighting cancer “a free day of fun, food and time with their family in a safe environment…[including] basketball activities, arts and crafts, carnival activities and many popular local child entertainers.” 

At the time of the first Swish for the Cure, Elite Camps was not the expansive chain of basketball camps that it is today. While Rudnick isn’t one to consider herself a philanthropist out of modesty, she would concede that philanthropy is a lot like playing basketball. Effective philanthropy fills a void in society in the same way that an effective player meets the needs of their team. It can be something small, like rebounding, or something more pronounced like accepting a leadership role.

Will a U of T student one day discover the cure for cancer? The Laboratory Medicine and Pathobiology Student Union (LMPSU) certainly hopes so.

Last week, the group hosted its annual conference, “Innovations in Immunotherapy: Conference on Curing Cancer and Autoimmunity” on the treatment’s medical potential.

Immunotherapy uses the body’s own immune system to fight disease, and is currently being  developed for treating autoimmune diseases and cancer, which currently affect 50 million North Americans. Cancer kills about 78, 000 people per year in Canada alone.

Co-presidents of the LMPSU, Charles Lee and Jelena Tanic, explained that they focused on immunotherapy precisely for the promise the treatment demonstrates. “Although it is in its infancy, immunotherapy can overcome numerous limitations of traditional treatments, and we wanted to highlight its promise,” Lee explained. “Some of the most amazing discoveries are being made right here at U of T. We wanted other undergraduate students to be inspired and also pursue research in these exciting fields.”

Audience participation at the conference. Courtesy Charles K. Lee.

With over 200 attendees and seven distinguished researchers as speakers, the conference led to lively discussion and debate. Whether or not immunotherapy will be as successful as one hopes to be remains to be seen. However, as noted by Dr. Alan Lazarus of the Department of Laboratory Medicine and Pathobiology, “[It’s] exciting when you don’t know the answer … You don’t know which [method] will be successful.”

The conference began with a lecture from Dr. Juan Carlos Zúñiga-Pflücker, the chair of U of T’s Department of Immunology, on his research in generating functional T cells in vitro for bone marrow transplants in individuals with defective or no T cells. As a patient’s cancer treatment progresses, there is often a period of immune deficiency that could be mediated with these transplants. 

Zúñiga-Pflücker’s talk was followed by a talk from Dr. Goetz Ehrhardt, also from U of T’s immunology department, who presented his research on using antibodies from sea-lampreys to diagnose cancer with greater accuracy than antibodies in use today.

The third lecturer, Dr. Lazarus, discussed the use of intravenous immunoglobulins and monoclonal antibodies to treat autoimmune disorders. He specifically spoke about thrombocytopenia, a condition characterized by a decreased platelet count in the body. 

Later in the day, a panel discussion on the concerns surrounding immunotherapy began. Since immunotherapy is just beginning clinical trials, there are concerns about its effectiveness and whether or not it can reasonably extend a person’s life more than if the patient were left untreated.

Overall, the LMPSU’s conference was a success; it managed to educate the general public on what immunotherapies are, and what they can do for treating disease. One can only hope that research can be translated into successful treatments, in the future.

For many recipients of organ transplants who have survived their surgeries, the danger is not quite over, according to new research at the University of Toronto.

Solid organ transplant recipients (SOTRs) are three times more likely to die of cancer than their peers in the general population, regardless of age, sex, or transplanted organ says the recent report.

This retrospective study identified 11,061 organ recipient patients with kidney, liver, heart, and lung transplants in Ontario between 1991 and 2010.

According to the study, one-fifth of the mortalities in this population were cancer-related. The results were consistent regardless of transplanted organ, and regardless of age or sex of the patient.“[Patients] are dying sooner after transplantation,” said Dr. Sergio A. Acuna, lead author of the study and PhD student in clinical epidemiology at the University of Toronto. “Cancer is cutting… their life expectancies [short].”

The increased risk in post-transplant patients is reported to be highest for children, and lowest among patients above the age of 60. Cancer is the second-leading cause of death among SOTRs and although cardiovascular disease has always been known as the leading cause of death, little prior research has been done on the burden of cancer in these populations.

Prior to this study, a paper was published on the role of cancer in kidney transplant recipients. A major flaw in that study, noted by Acuna, was that “40 per cent [of] their causes of death were unknown… Our data is more contemporary.”

Additional mortality factors were controlled for in the study conducted by Acuna, including cardiovascular disease, organ rejection, and infections related to immunosuppression, and in doing so the study isolated cancer as the cause of death.

The study confirmed that cancer outcomes for SOTRs are worse than that of their peers in the general population, and researchers are now looking into the causes behind this disparity.

The researchers hypothesize that the increase in cancer risk may be due to the medication required by SOTRs to suppress the immune system in order avoid organ rejection.

Another possibility is simply the difference in treatment options between SOTR patients and non-transplant patients.

“That [difference] is one of the aspects we are going to explore in the future,” said Acuna. “…we are going to compare the differences in the way transplant patients with cancer and non-transplant patients with cancer are managed in terms of chemotherapy, radiotherapy, and surgery.”

As the median age of transplant recipients increases, the incidences of cancer are expected to grow. This is primarily a result of higher post-transplant survival rates, as patients are now living long enough for cancer to be an issue.

“There is not [currently] a specific screening recommendation for transplant recipients. In fact, the only recommendations that exist are extensions [of the recommendations] for the general population.”

A major concern for the researchers is that patients would become more hesitant to receive organ transplants, in light of this research. “In no way are we suggesting that they should not receive the transplant because of the risk of cancer,” Acuna emphasized. But rather, measures must be taken to “ensure that [the organs] are used in the best way, [that is, to] provide these patients with the longest life expectancy that we can give them.”